Assertio Q4 net product sales fell 56.7% to USD 12.8 million as adjusted EBITDA was USD -4.1 million

Reuters

Mar 17

Assertio Q4 net product sales fell 56.7% to USD 12.8 million as adjusted EBITDA was USD -4.1 million

Assertio published a press release reporting fourth-quarter and full-year 2025 financial results and issued full-year 2026 guidance. Q4 net product sales were USD 12.82 million, down 56.7%, driven by a planned Rolvedon sell-in in Q3 that covered the next two quarters of demand during a distribution transition. Q4 net loss was USD 11.93 million and adjusted EBITDA was a loss of USD 4.11 million. FY net product sales were USD 117.1 million and adjusted EBITDA was USD 22.71 million, up 24.1%. Chief Executive Officer Mark Reisenauer said the company is prioritizing building an oncology portfolio around Rolvedon and expects FY 2026 net product sales of USD 110 million to USD 125 million and adjusted EBITDA of USD 28 million to USD 40 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assertio Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603161605BIZWIRE_USPR_____20260316_BW015407) on March 16, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2620499507"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620499507\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620499507?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620499507","market":"fut","top_or_hot":-1,"title":"Assertio Q4 net product sales fell 56.7% to USD 12.8 million as adjusted EBITDA was USD -4.1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Assertio Q4 net product sales fell 56.7% to USD 12.8 million as adjusted EBITDA was USD -4.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Assertio published a press release reporting fourth-quarter and full-year 2025 financial results and issued full-year 2026 guidance. Q4 net product sales were USD 12.82 million, down 56.7%, driven by a planned Rolvedon sell-in in Q3 that covered the next two quarters of demand during a distribution transition. Q4 net loss was USD 11.93 million and adjusted EBITDA was a loss of USD 4.11 million. FY net product sales were USD 117.1 million and adjusted EBITDA was USD 22.71 million, up 24.1%. Chief Executive Officer Mark Reisenauer said the company is prioritizing building an oncology portfolio around Rolvedon and expects FY 2026 net product sales of USD 110 million to USD 125 million and adjusted EBITDA of USD 28 million to USD 40 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assertio Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603161605BIZWIRE_USPR_____20260316_BW015407) on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assertio Q4 net product sales fell 56.7% to USD 12.8 million as adjusted EBITDA was USD -4.1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssertio Q4 net product sales fell 56.7% to USD 12.8 million as adjusted EBITDA was USD -4.1 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-17 04:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Assertio Q4 net product sales fell 56.7% to USD 12.8 million as adjusted EBITDA was USD -4.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Assertio published a press release reporting fourth-quarter and full-year 2025 financial results and issued full-year 2026 guidance. Q4 net product sales were USD 12.82 million, down 56.7%, driven by a planned Rolvedon sell-in in Q3 that covered the next two quarters of demand during a distribution transition. Q4 net loss was USD 11.93 million and adjusted EBITDA was a loss of USD 4.11 million. FY net product sales were USD 117.1 million and adjusted EBITDA was USD 22.71 million, up 24.1%. Chief Executive Officer Mark Reisenauer said the company is prioritizing building an oncology portfolio around Rolvedon and expects FY 2026 net product sales of USD 110 million to USD 125 million and adjusted EBITDA of USD 28 million to USD 40 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assertio Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603161605BIZWIRE_USPR_____20260316_BW015407) on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL8fwWRp:1","article_id":"2620499507","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620499507","pubTimestamp":1773691604,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Assertio published a press release reporting fourth-quarter and full-year 2025 financial results and issued full-year 2026 guidance. Q4 net product sales were USD 12.82 million, down 56.7%, driven by a planned Rolvedon sell-in in Q3 that covered the next two quarters of demand during a distribution transition. Q4 net loss was USD 11.93 million and adjusted EBITDA was a loss of USD 4.11 million. FY net product sales were USD 117.1 million and adjusted EBITDA was USD 22.71 million, up 24.1%. Chief Executive Officer Mark Reisenauer said the company is prioritizing building an oncology portfolio around Rolvedon and expects FY 2026 net product sales of USD 110 million to USD 125 million and adjusted EBITDA of USD 28 million to USD 40 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ASRT":"Assertio Holdings, Inc."},"translate_title":"Assertio第四季度产品净销售额下降56.7%至1,280万美元，调整后EBITDA为-410万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASRT":0.9},"content_text":"Assertio Q4 net product sales fell 56.7% to USD 12.8 million as adjusted EBITDA was USD -4.1 million\n    \n\n        Assertio published a press release reporting fourth-quarter and full-year 2025 financial results and issued full-year 2026 guidance. Q4 net product sales were USD 12.82 million, down 56.7%, driven by a planned Rolvedon sell-in in Q3 that covered the next two quarters of demand during a distribution transition. Q4 net loss was USD 11.93 million and adjusted EBITDA was a loss of USD 4.11 million. FY net product sales were USD 117.1 million and adjusted EBITDA was USD 22.71 million, up 24.1%. Chief Executive Officer Mark Reisenauer said the company is prioritizing building an oncology portfolio around Rolvedon and expects FY 2026 net product sales of USD 110 million to USD 125 million and adjusted EBITDA of USD 28 million to USD 40 million.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assertio Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603161605BIZWIRE_USPR_____20260316_BW015407) on March 16, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}